Selective delivery of RNA-based drugs inside the tumoral microenvironment exploiting the tropism of attenuated Listeria monocytogenes (Lmat)


Laura Poliseno



Institute of Clinical Physiology, National Research Council



Our group will conjugate the ASO with the “intelligent carrier” attenuated Listeria monocytogenes (Lmat). This strategy will allow us to couple strong on-target effects (Lmat-induced stimulation of host immune system against cancer cells plus ASO-induced reduction of tumor neo-vasculature) with minimal side effects, given that Lmat has selective tropism for the tumor microenvironment. Together with Dr. Ghigna’s group, we will test safety and effectiveness of ASO-Lmat in vitro, ex vivo and in vivo.

Relevant publications

  1. Lepori I, Roncetti M, Vitiello M, Barresi E, Tentori PM, Baldanzi C, Evangelista M, Signore G, Tedeschi L, Gravekamp C, Cardarelli F, Taliani S, Da Settimo F, Siegrist MS and Poliseno L. Enhancing the anticancer activity of attenuated Listeria monocytogenes by cell wall functionalization with “clickable” doxorubicin. Research Square 2023 DOI:
  2. Vitiello M, Evangelista M, Di Lascio N, Kusmic C, Massa A, Orso F, Sarti S, Marranci A, Rodzik K, Germelli L, Chandra D, Salvetti A, Pucci A, Taverna D, Faita F, Gravekamp C and Poliseno L. Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma. Oncogene. 2019; 38:3756-3762.

Related Projects

PI: Claudia Coronnello